Secondary neoplasms in two patients treated with purine analogues.
Schlaifer
D
D
Riga-Huguet
F
F
Pris
J
J
Brousset
P
P
Delannoy
A
A
Bosly
A
A
D000208:Acute Disease; D000368:Aged; D017338:Cladribine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007938:Leukemia / Q000139:chemically induced*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000139:chemically induced*; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy
D017338:Cladribine; D014740:Vidarabine; C024352:fludarabine